Picture loading failed.

Anti-TGFB therapeutic antibody (Pre-made Fresolimumab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Fresolimumab (GC1008) is a human monoclonal antibody and an immunomodulator. It is intended for the treatment of idiopathic pulmonary fibrosis (IPF), focal segmental glomerulosclerosis, and cancer (kidney cancer and melanoma).

Order information

Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-223-1mg 1mg 3090
GMP-Bios-ab-223-10mg 10mg 21890
GMP-Bios-ab-223-100mg 100mg 148000
GMP-Bios-ab-223-xmg ≥100mg Inquiry
Shipping Cost: 760.00


Products Name (INN Index) Anti-TGFB therapeutic antibody (Pre-made Fresolimumab biosimilar,Whole mAb)
INN Name Fresolimumab
FormatWhole mAb
Species ReactivityHuman
CH1 IsotypeIgG4
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-I
Est. StatusDiscontinued
100% SI StructureNone
99% SI Structure3eo0:DC:BA/4kxz:JI:HL:NM:QP/4kv5:EF:GK:HL:JI/3eo1:BA:ED:KJ:HG
95-98% SI StructureNone
Year Proposed2009
Year Recommended2010
CompaniesCambridge Antibody Technology;Baylor College of Medicine;Genzyme Corporation;Sanofi Genzyme
Conditions Approvedna
Conditions Activena
Conditions DiscontinuedFibrosis;Malignant melanoma;Pulmonary fibrosis;Renal cancer;Focal segmental glomerulosclerosis;Osteogenesis imperfecta
Development TechCAT Phage Display